CliffBio
small molecule

VYONDYS 53

GOLODIRSEN

Loss of exclusivityJune 2028latest FDA-listed patent expiry
CompanySarepta Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand nameVYONDYS 53
Active ingredientGOLODIRSEN
Strength100MG/2ML (50MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalDecember 2019
Marketing statusRX

Listed patents

PatentExpiresType
RE47691June 2028product

Regulatory exclusivity

CodeExpires
ODE-280December 2026

More from Sarepta Therapeutics

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.